ONCA OVARIAN TOPOTECAN Q3WEEK - PRL47
Topotecan(1.25)d1-5; q21d x 6 cycles

Cycle length = 21 days
 
Lab Orders
Lab Parameters to Assess:  ANC greater than 1,500; platelets greater than 100,000; CrCl greater than 39 mL/min
Baseline Labs:  CBC, SCr, Hep-B sAg, Hep-B cAb
Labs before each treatment:  Day 1: CBC, SCr
 
Premedications
0.9% saline 500 mL.  Infuse at 20 mL/hr as primary line to keep vein open.
Antiemetics  (Level 2b): 
Prochlorperazine (COMPAZINE) 10 mg tab. Give 1 tablet PO 30 minutes before chemotherapy.
 
Treatment
Topotecan (HYCAMTIN) 1.25 mg/M2/dose (= ____ mg) in 0.9% saline 100 mL IVPB.  Infuse over 30 minutes.  Give days 1, 2, 3, 4, 5 of each cycle.
 
PRN and HSR Medications
LORazepam (ATIVAN) 0.5 mg tab.  Give 1 tablet PO PRN nausea, vomiting or anxiety.  May repeat one time in 30 minutes and every 4 hours prn thereafter.
LORazepam (ATIVAN) 0.5 mg injection.  Inject 0.5 mg IV push PRN nausea, vomiting or anxiety if unable to tolerate oral formulation.  May repeat one time in 30 minutes and every 4 hours prn thereafter.
Acetaminophen (TYLENOL) 325 mg tab.  Take 2 tablets PO every 4 hours if needed for fever (greater than 100.4 F), myalgias, arthralgias or headache.
Alteplase (CATHFLO ACTIVASE) 2 mg injection.  Instill dose one time PRN into occluded central venous catheter per nursing procedure. 
Hydrocortisone (SOLU-CORTEF) 100 mg.  Give IV push one time, if needed for hypersensitivity reaction due to chemotherapy.
DiphenhydrAMINE (BENADRYL) 50 mg.  Give IV push one time, if needed for hypersensitivity reaction due to chemotherapy. 
 
Nursing
Begin 0.9% saline as primary line to keep vein open.
Verify that patient meets the lab parameters for administration. 
Perform assessment for toxicity and tolerance.
Flush IV line with minimum of 30 mL of primary solution before and after each chemotherapy drug.
Review discharge medications, instructions and future appointments. 
 
References
Manufacturers Package Insert (Hospira)
http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=1d4e1cce-c57e-4a8b-be96-f95a2778e221
Sehouli J, et al. J Clin Oncol, 2011 29:242-248 
http://jco.ascopubs.org/content/29/2/242.full.pdf+html
Protocol (therapy) has been modified from reference based on consensus of collaborative build group - see FAQ Rationale
